Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Medicenna Therapeutics Corp (MDNA.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 62,872
  • Shares Outstanding, K 28,578
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,465 K
  • 60-Month Beta 1.54
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 17.94
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.20
  • Most Recent Earnings -0.07 on 12/31/18
  • Next Earnings Date 06/26/19
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.11
  • Number of Estimates 2
  • High Estimate -0.08
  • Low Estimate -0.14
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -120.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.66 +209.09%
on 05/23/19
2.38 -14.29%
on 06/14/19
+1.36 (+200.00%)
since 05/17/19
3-Month
0.64 +218.75%
on 04/22/19
2.38 -14.29%
on 06/14/19
+1.26 (+161.54%)
since 03/15/19
52-Week
0.64 +218.75%
on 04/22/19
2.38 -14.29%
on 06/14/19
+0.59 (+40.69%)
since 06/14/18

Most Recent Stories

More News
Medicenna To Host Key Opinion Leader Call Focused on MDNA55 Recurrent Glioblastoma Program and Preliminary Top-Line Results

TORONTO and HOUSTON , June 13, 2019 / CNW/ - Medicenna Therapeutics Corp.  (" Medicenna " or "the Company ") (TSX: MDNA, OTCQB: MDNAF), a clinical stage Immuno-Oncology company, today...

MDNAF : 1.5400 (-9.14%)
MDNA.TO : 2.04 (-7.27%)
Medicenna To Host Key Opinion Leader Call Focused on MDNA55 Recurrent Glioblastoma Program and Preliminary Top-Line Results

Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage Immuno-Oncology company, today announced that it will host a Key Opinion Leader call and webcast...

MDNA.TO : 2.04 (-7.27%)
Medicenna To Host Key Opinion Leader Call Focused on MDNA55 Recurrent Glioblastoma Program and Preliminary Top-Line Results

Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage Immuno-Oncology company, today announced that it will host a Key Opinion Leader call and webcast...

MDNA.TO : 2.04 (-7.27%)
Medicenna To Present Preliminary Top-Line Results on MDNA55 at the Immuno-Oncology Pharma Congress

Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage Immuno-Oncology company, today announced that it will present preliminary top-line results from...

MDNA.TO : 2.04 (-7.27%)
Medicenna to Present at the 9th Annual LD Micro Invitational

Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, is pleased to announce that Dr. Fahar Merchant, Chairman, President and...

MDNA.TO : 2.04 (-7.27%)
Medicenna Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting

TORONTO and HOUSTON , May 16, 2019 /PRNewswire/ - Medicenna Therapeutics Corp.  (" Medicenna " or "the Company ") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company,...

MDNAF : 1.5400 (-9.14%)
MDNA.TO : 2.04 (-7.27%)
Medicenna Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting

Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced that Dr. Dina Randazzo of Duke University, will present...

MDNA.TO : 2.04 (-7.27%)
Medicenna Receives Non-Dilutive Grant Payment

TORONTO and HOUSTON , May 1, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, announced today...

MDNAF : 1.5400 (-9.14%)
MDNA.TO : 2.04 (-7.27%)
Medicenna Receives Non-Dilutive Grant Payment

Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, announced today that it has received US$757,940 (approximately, CD$1.02M)...

MDNA.TO : 2.04 (-7.27%)
Medicenna to Present at Bloom Burton & Co. Healthcare Investor Conference 2019

Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, is pleased to announce that executives from Medicenna, Dr. Fahar Merchant,...

MDNA.TO : 2.04 (-7.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Key Turning Points

2nd Resistance Point 2.54
1st Resistance Point 2.37
Last Price 2.04
1st Support Level 2.04
2nd Support Level 1.88

See More

52-Week High 2.38
Last Price 2.04
Fibonacci 61.8% 1.72
Fibonacci 50% 1.51
Fibonacci 38.2% 1.30
52-Week Low 0.64

See More

Business Summary

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines (IL4-ECs) that specifically...

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar